This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.
After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
STRASS 2
Histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of retroperitoneal space or infra-peritoneal spaces of pelvis.
Any grade LMS can be included
Minimum size of LMS tumor should be 5 cm
Sarcoma originating from bone structure, abdominal or gynecological viscera
Extension through the sciatic notch or across the diaphragm
Metastatic disease
Any previous surgery (excluding diagnostic biopsy), radiotherapy or systemic therapy for the present tumour
European Organisation for Research and Treatment of Cancer - EORTC
Lead sponsor
Canadian Cancer Trials Group
Collaborator
ECOG-ACRIN Cancer Research Group
Collaborator
Anticancer Fund, Belgium
Collaborator
Australia and New Zealand Sarcoma Association
Collaborator
Japan Clinical Oncology Group
Collaborator